MedTrace Logo

Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

NCT01940146 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2019-05-03

Study results available
· View outcomes & findings →

Summary

The study will assess the efficacy and safety of SPARC1310 when compared to placebo and active control

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

SPARC Placebo

Placebo

DRUG

SPARC1310 I

SPARC1310 I

DRUG

SPARC1310 II

SPARC1310 II

DRUG

SPARC1310 III

SPARC1310 III

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Principal Investigators

  • Shravanti Bhowmik, MD · Sun Pharma Advanced Research Company Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01940146 on ClinicalTrials.gov